| Bioactivity | Tilogotamab (GEN-1029) is an agonistic hexamer formation-enhanced mixture of two antibodies that target two separate epitopes on death receptor type 5 (DR5). Tilogotamab specifically binds to and activates DR5. Tilogotamab can be used for the research of multiple myeloma (MM)[1]. |
| In Vivo | Tilogotamab (20 μg/mL; 24 h) 对原代 MM 细胞具有很强的细胞毒性[1]。Tilogotamab 是 2 种非竞争性 DR5 特异性免疫球蛋白 G1 (IgG1) 抗体的混合物，每种抗体的 Fc 域均有一个 E430G 突变。这种突变增强了 Fc-Fc 相互作用，导致抗体六聚化，随后是 DR5 分子的 FcγR 非依赖性聚类[1]。 |
| Name | Tilogotamab |
| CAS | 2109731-10-2 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Horst HJ, et, al. Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma. Blood Adv. 2021 Apr 27;5(8):2165-2172. |